Cambridge Healthtech Institute’s 8th Annual
Bi & Multispecific Engineering
August 11, 2025
Explore the cutting-edge advancements and address critical challenges at Cambridge Healthtech Institute's 8th Annual Bi & Multispecific Engineering conference. This year’s program will spotlight the rise of bispecific T cell engagers and bispecific antibodies, offering innovative solutions and data-driven strategies to enhance their efficacy in solid tumors. Explore nanobody applications to multispecific antibodies, construct optimization, and the data-driven designs that are shaping the future of cancer immunotherapy. Topics will delve into overcoming resistance mechanisms, improving tissue penetration, and addressing toxicity, and utilizing the five rights framework for effective target selection. Join us to discover how computational tools and next-generation design approaches are transforming bi/multispecific antibody engineering for therapeutic success.
Who should attend: Biotech Founders in IO, Pharma Directors, Principal and Senior Scientists, IO Professors and Post-Docs, Immunologists and Oncologists, Computational Biologists Regulatory Affairs Specialists, Clinical Trial Managers, and those researching bispecific/multispecific antibodies and cell therapy.
Coverage will include, but is not limited to:
- The Rise of Bispecific T Cell Engagers and Bispecific Antibodies: Challenges and Opportunities
- Machine learning and data science in BiTE developments
- BiTE therapy successes in Hematological Malignancies applied to solid tumors
- Five rights of target selection for bispecific immune cell engagers
- Addressing efficacy issues with BiTE therapy such as:
- Overcoming resistance mechanisms
- Combating toxicity in solid tumors
- Improving solid tissue penetration
- Optimizing Construct and Data-Driven Design
- Nanobody applications to bi/multispecific antibodies
- Innovations in construct design for bispecifics being applied to solid tumors
- Selection and improving targeting
- Enhancing efficacy
- ML and data science-driven design for bispecific and multispecific antibody development
The deadline for priority consideration is January 31, 2025.
All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
Opportunities for Participation: